Lineage Cell Therapeutics shares rise 8.71% intraday after Mesoblast's U.S. origin product designation.

Lineage Cell Therapeutics, Inc. rose 8.71% in intraday trading, with the company's stock price increase potentially influenced by the news that Mesoblast Limited's allogeneic cell therapy products, including Ryoncil®, are designated as U.S. origin products not subject to tariffs on imported branded or patented pharmaceutical products. This designation aligns with U.S. FDA and Customs regulatory guidance, which could positively impact the broader cell therapy sector, including Lineage Cell Therapeutics, Inc.